Boots owner rejects accusations it overcharged NHS for cancer mouthwash

Written by Joseph Nordqvist

Published: 05:18, May 27, 2018

Walgreens Boots Alliance has rejected accusations that it has been overcharging the NHS for a mouthwash used by cancer patients.

The announcement by the company follows an investigation by the Times newspaper which found that Boots charged the NHS £3,220 for a medicinal mouthwash that can cost as low £93.

The Times claims that Boots used a legal loophole which lets suppliers set their own prices for these drugs. The mouthwash was ordered from a supplier owned by Boot’s parent company.

The paper said Boots charged £3,219 to supply three 200ml bottles from 2013-2017, then charged £3,220 for the same amount, £1,843 for an 800ml treatment, £1,989.12 for 800ml and £6,374.25 for 2,600ml.

Meanwhile, a pharmacy in West Sussex charged £31.14 for one 200ml bottle in 2016.

Walgreens Boots Alliance is the US-based parent company of the UK pharmacy Boots.

A Walgreens Boots Alliance spokesman said: “We firmly reject accusations of overcharging the NHS.

“Our senior company leaders have already recently met with officials from the Department of Health to discuss the specials products.”

Health Minister Steve Brine has called for the Competition and Markets Authority to carry out an investigation into the matter.

Brine said the public would take “an extremely dim view of any company found to be exploiting our NHS and patients”.

“We have asked the Competition and Markets Authority to consider investigating as a priority,” he said.

Adding:

“We have changed the law to enable us to place pharmacies and manufacturers under much stronger scrutiny.

“Where there is evidence of collusion between pharmacies and suppliers swift action will be taken to claw back funds and penalise offenders.”

 

Joseph Nordqvist Avatar

Other News

Japan’s household financial assets hit a record ¥2,519 trillion. What that measures

Sep 17, 2026

Canada welcomes EU associate-member proposal, but terms are undefined

Sep 17, 2026

Softcat agrees $1.05B GDT acquisition to expand US data-centre services

Sep 17, 2026

Bank Rate held at 3.75% in the UK as energy prices sharpen inflation risk

Sep 17, 2026

East African Community trade reaches $52.3bn as exports drive surplus

Sep 16, 2026

Canada says its investment summit mobilised nearly C$500bn. What does that actually mean?

Sep 16, 2026

May Mobility agrees $1.4B SPAC deal, bets on asset-light robotaxi model

Sep 16, 2026

Fed raises rates to 3.75% to 4.00% as inflation remains elevated

Sep 16, 2026

IBM-backed Anderon finalizes up to $1B US quantum foundry award

Sep 16, 2026

WTO puts the cost of trade fragmentation at up to 10% of global GDP

Sep 15, 2026

Salesforce launches Koa, a CRM reasoning model built on Nvidia’s Nemotron

Sep 15, 2026

Could humanoid AI companions ever replace human partners?

Sep 15, 2026

IEA forecasts record global coal demand after gas prices climb

Sep 15, 2026

UK government to pursue public acquisition of Speciality Steel UK

Sep 15, 2026

IMF says global current-account gaps widened in 2025, led by China and the United States

Sep 14, 2026

Alan Lovell takes over as British Steel chair as government pursues turnaround

Sep 14, 2026

Plumbing or college: weighing pay, training and AI exposure

Sep 13, 2026

Why more advanced VR equipment does not always feel more real

Sep 13, 2026

VR pilot training shows promise before a student’s first real flight

Sep 13, 2026

Family businesses face a gap between succession plans and readiness

Sep 13, 2026